株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

レット症候群:パイプライン製品の分析

Rett Syndrome - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 359401
出版日 ページ情報 英文 114 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.69円で換算しております。
Back to Top
レット症候群:パイプライン製品の分析 Rett Syndrome - Pipeline Review, H1 2018
出版日: 2018年04月10日 ページ情報: 英文 114 Pages
概要

当レポートでは、レット症候群治療薬の開発状況について調査分析しており、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどの情報を提供しています。

イントロダクション

  • 調査範囲

レット症候群の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

レット症候群:企業で開発中の治療薬

レット症候群:大学/機関で研究中の治療薬

レット症候群:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

レット症候群:企業で開発中の製品

レット症候群:大学/機関で研究中の製品

レット症候群の治療薬開発に従事している企業

  • Anavex Life Sciences Corp.
  • ArmaGen Inc.
  • Edison Pharmaceuticals, Inc.
  • GW Pharmaceuticals Plc
  • 田辺三菱製薬
  • Neuren Pharmaceuticals Limited
  • Neurolixis Inc.
  • Newron Pharmaceuticals S.p.A.
  • OPKO Health, Inc.
  • Oryzon Genomics S.A.
  • PharmatrophiX, Inc.
  • Raptor Pharmaceutical Corp.
  • Sage Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.

レット症候群:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

レット症候群:最近のパイプライン動向

レット症候群:休止中のプロジェクト

レット症候群:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

目次
Product Code: GMDHC10332IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H1 2018, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape.

Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rett Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rett Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rett Syndrome - Overview
    • Rett Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rett Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rett Syndrome - Companies Involved in Therapeutics Development
    • AMO Pharma Ltd
    • Amorsa Therapeutics Inc
    • Anavex Life Sciences Corp
    • ArmaGen Inc
    • AveXis Inc
    • Biohaven Pharmaceutical Holding Company Ltd
    • Eloxx Pharmaceuticals Inc
    • GW Pharmaceuticals Plc
    • Mitochon Pharmaceuticals Inc
    • Mitsubishi Tanabe Pharma Corp
    • Neuren Pharmaceuticals Ltd
    • Neurolixis Inc
    • Newron Pharmaceuticals SpA
    • OPKO Health Inc
    • Ultragenyx Pharmaceutical Inc
  • Rett Syndrome - Drug Profiles
    • ANAVEX-273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVXS-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BHV-5000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bryostatin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPT-157633 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELX-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fingolimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene therapy to Activate MECP2 for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate MECP2 Protein for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWP-42006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-22A4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sarizotan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize mGlu5 for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize mGlu7 for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Pervasive Developmental Disorder and Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tianeptine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trofinetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rett Syndrome - Dormant Projects
  • Rett Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2018: Patent published on novel serotonin 5-HT1A receptor agonists NLX-101
      • Jan 18, 2018: Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist
      • Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer's Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer's Disease Meeting
      • Oct 25, 2017: Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting
      • Oct 13, 2017: Neuren confirms Phase 3 plan for Rett syndrome at FDA Meeting
      • Oct 05, 2017: Presentations and Publication for Neuren's Rett Syndrome Clinical Trials
      • Jul 27, 2017: Drug Improves Brain Performance in Rett Syndrome Mice
      • Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
      • Jul 20, 2017: Neuren granted Type B Meeting with FDA for Rett syndrome
      • Jul 06, 2017: Biohavens BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome
      • Jun 29, 2017: Neuren secures funding for key preparatory activities for Rett syndrome Phase 3 trial
      • May 31, 2017: Neuren announces grant of two new patents for trofinetide to 2032
      • May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
      • May 17, 2017: Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age
      • Mar 22, 2017: Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Rett Syndrome, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Rett Syndrome - Pipeline by AMO Pharma Ltd, H1 2018
  • Rett Syndrome - Pipeline by Amorsa Therapeutics Inc, H1 2018
  • Rett Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2018
  • Rett Syndrome - Pipeline by ArmaGen Inc, H1 2018
  • Rett Syndrome - Pipeline by AveXis Inc, H1 2018
  • Rett Syndrome - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
  • Rett Syndrome - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
  • Rett Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2018
  • Rett Syndrome - Pipeline by Mitochon Pharmaceuticals Inc, H1 2018
  • Rett Syndrome - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
  • Rett Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H1 2018
  • Rett Syndrome - Pipeline by Neurolixis Inc, H1 2018
  • Rett Syndrome - Pipeline by Newron Pharmaceuticals SpA, H1 2018
  • Rett Syndrome - Pipeline by OPKO Health Inc, H1 2018
  • Rett Syndrome - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018
  • Rett Syndrome - Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development for Rett Syndrome, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top